{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:15:08Z","timestamp":1791375308009,"version":"4.3.1"},"reference-count":86,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Anti-B-cell maturation antigen therapies consisting of bispecific antibodies, antibody\u2013drug conjugates, and chimeric antigen receptor T cells have shown promising results in relapsed refractory multiple myeloma (RRMM). However, the severe side effects include cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, cytopenia(s), infections, hemophagocytic lymphohistiocytosis, and organ toxicity, which could sometimes be life-threatening. This review focuses on these most common complications post-BCMA therapy. We discussed the risk factors, pathogenesis, clinical features associated with these complications, and how to prevent and treat them. We included four original studies for this focused review. All four agents (idecabtagene vicleucel, ciltacabtagene autoleucel, teclistamab, belantamab mafodotin) have received FDA approval for adult RRMM patients. We went through the FDA access data packages of the approved agents to outline stepwise management of the complications for better patient outcomes.<\/jats:p>","DOI":"10.3390\/jcm12175539","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T08:42:20Z","timestamp":1692952940000},"page":"5539","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0081-9502","authenticated-orcid":false,"given":"Razwana","family":"Khanam","sequence":"first","affiliation":[{"name":"Department of Hospital Medicine, Baystate Medical Center, Springfield, MA 01199, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Faiman","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Batool","sequence":"additional","affiliation":[{"name":"Department of Hospital Medicine, Carle Health Methodist Hospital, Peoria, IL 61636, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Musa","family":"Najmuddin","sequence":"additional","affiliation":[{"name":"The Wright Center for Graduate Medical Education, Scranton, PA 18505, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0062-1811","authenticated-orcid":false,"given":"Rana","family":"Usman","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Science Center, Memphis, TN 38163, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Kuriakose","sequence":"additional","affiliation":[{"name":"Department of Hospital Medicine, UPMC Mercy Hospital, Pittsburgh, PA 15219, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arooj","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology and Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ebad Ur","family":"Rehman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Rawalpindi Medical University, Rawalpindi 46000, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0789-3310","authenticated-orcid":false,"given":"Zinath","family":"Roksana","sequence":"additional","affiliation":[{"name":"Sheikh Hasina National Institute of Burn and Plastic Surgery, Dhaka 1217, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain","family":"Syed","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-7439","authenticated-orcid":false,"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahzad","family":"Raza","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1586\/17474086.2014.882764","article-title":"Current strategies for treatment of relapsed\/refractory multiple myeloma","volume":"7","author":"Laubach","year":"2014","journal-title":"Expert Rev. Hematol."},{"key":"ref_2","unstructured":"National Cancer Institute (2023, March 11). Surveillance, Epidemiology, and End Results Program, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/intimm\/10.11.1693","article-title":"The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily","volume":"10","author":"Madry","year":"1998","journal-title":"Int. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1021\/bi048227k","article-title":"Selectivity of BAFF\/BLyS and APRIL for binding to the TNF family receptors BAFFR\/BR3 and BCMA","volume":"44","author":"Day","year":"2005","journal-title":"Biochemistry"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1182\/blood-2009-09-243535","article-title":"Classical and\/or alternative NF-\u03baB pathway activation in multiple myeloma","volume":"115","author":"Demchenko","year":"2010","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/med.21574","article-title":"JNK signaling in cancer cell survival","volume":"39","author":"Wu","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.35.15_suppl.3010","article-title":"First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed\/refractory multiple myeloma: Updated results","volume":"35","author":"Berdeja","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"LBA3001","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA3001","article-title":"Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory\/relapsed multiple myeloma","volume":"35","author":"Fan","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_10","unstructured":"(2023, March 11). FDA Approves Idecabtagene Vicleucel for Multiple Myeloma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-idecabtagene-vicleucel-multiple-myeloma."},{"key":"ref_11","unstructured":"(2023, March 11). FDA Approves Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma."},{"key":"ref_12","unstructured":"(2023, March 11). GSK Provides Update on DREAMM-3 Phase III Trial for Blenrep in Relapsed\/Refractory Multiple Myeloma. Available online: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep\/."},{"key":"ref_13","unstructured":"(2023, March 11). FDA Approves Teclistamab-Cqyv for Relapsed or Refractory Multiple Myeloma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/14712598.2019.1641196","article-title":"B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma","volume":"19","author":"Tai","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1182\/blood-2022-162615","article-title":"KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation","volume":"140","author":"Dhodapkar","year":"2022","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","article-title":"CARTITUDE-1 final results: Phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1200\/JCO.2023.41.16_suppl.8011","article-title":"Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) \u00d7 CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Moreau","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.1182\/blood-2022-164877","article-title":"Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial","volume":"140","author":"Nooka","year":"2022","journal-title":"Blood"},{"key":"ref_19","unstructured":"(2023, March 11). Package Insert for ABECMA, Available online: https:\/\/www.fda.gov\/media\/147055\/download."},{"key":"ref_20","unstructured":"(2023, March 11). Package Insert for CARVYKTI, Available online: https:\/\/www.fda.gov\/media\/156560\/download."},{"key":"ref_21","unstructured":"(2023, March 11). Package Insert for TECVAYLI, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761291s000lbl.pdf."},{"key":"ref_22","unstructured":"(2023, March 11). Package Insert for BLENREP, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761158s000lbl.pdf."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Ailawadhi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/01.HS9.0000829604.35383.e8","article-title":"P08: Cartitude-2 Update: Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen\u2013Directed Chimeric Antigen Receptor T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1\u20133 Prior Lines of Therapy","volume":"6","author":"Einsele","year":"2022","journal-title":"Hemasphere"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.HS9.0000936128.56463.c8","article-title":"B09 Cartitude-2 Cohort B 18-Month Follow-Up: Ciltacabtagene Autoleucel (Cilta-Cel), A Bcma-Directed Car-T Cell Therapy, In Patients With Multiple Myeloma (Mm) And Early Relapse After Initial Therapy","volume":"7","author":"Zweegman","year":"2023","journal-title":"HemaSphere"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e006699","DOI":"10.1136\/jitc-2023-006699","article-title":"Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy","volume":"11","author":"Lee","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","article-title":"Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells","volume":"43","author":"Offner","year":"2006","journal-title":"Mol. Immunol."},{"key":"ref_30","unstructured":"(2023, March 11). Pfizer\u2019s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizers-elranatamab-granted-fda-breakthrough-therapy."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1200\/JCO.2023.41.16_suppl.8039","article-title":"Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study","volume":"41","author":"Mohty","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_32","unstructured":"(2023, March 11). FDA Granted Accelerated Approval to Belantamab Mafodotin-Blml for Multiple Myeloma. Available online: https:\/\/www.esmo.org\/oncology-news\/fda-granted-accelerated-approval-to-belantamab-mafodotin-blmf-for-multiple-myeloma#:~:text=On%205%20August%202020%2C%20the,CD38%20monoclonal%20antibody%2C%20a%20proteasome."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8073","article-title":"Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14","volume":"40","author":"Hultcrantz","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1200\/JCO.2023.41.16_suppl.8007","article-title":"A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): DREAMM-3","volume":"41","author":"Weisel","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_35","unstructured":"(2023, July 23). DREAMM Trials for RRMM, Available online: https:\/\/clinicaltrials.gov\/search?cond=rrMM&term=DREAMM."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti\u2013B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transpl."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1080\/10428194.2019.1697814","article-title":"Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)","volume":"61","author":"Nahas","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Sanoyan, D.A., Seipel, K., Bacher, U., Kronig, M.-N., Porret, N., Wiedemann, G., Daskalakis, M., and Pabst, T. (2023). Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed\/refractory multiple myeloma patients. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-10824-3"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1182\/blood-2022-158801","article-title":"Teclistamab for Relapsed\/Refractory Multiple Myeloma: Real-World Experience in an Early Access Program","volume":"140","author":"Uttervall","year":"2022","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.18479","article-title":"Real-world experience with belantamab mafodotin therapy for relapsed\/refractory multiple myeloma: A multicentre retrospective study","volume":"200","author":"Shragai","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014Assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00277-022-04889-6","article-title":"Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells\u2014Single-center experience","volume":"101","author":"Perry","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"E399","DOI":"10.1002\/ajh.26313","article-title":"The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T-cell therapy","volume":"96","author":"Barreto","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41409-021-01526-0","article-title":"Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed\/refractory B-cell lymphoma","volume":"57","author":"Morin","year":"2022","journal-title":"Bone Marrow Transpl."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"E20","DOI":"10.1002\/ajh.25664","article-title":"Successful treatment of marrow failure after CARTs for myeloma by the infusion of cryopreserved stem cells","volume":"95","author":"Yan","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"101287","DOI":"10.1016\/j.beha.2021.101287","article-title":"Toxicities associated with adoptive cellular therapies","volume":"34","author":"Hansen","year":"2021","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: A population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Adv."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transpl."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Mohan, M., Chakraborty, R., Bal, S., Nellore, A., Baljevic, M., D\u2019Souza, A., Pappas, P.G., Berdeja, J.G., Callander, N., and Costa, L.J. (2023). Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma. Br. J. Haematol.","DOI":"10.1111\/bjh.18909"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-023-00808-8","article-title":"Infectious complications of bispecific antibody therapy in patients with multiple myeloma","volume":"13","author":"Sim","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of COVID-19","volume":"386","author":"Levin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Subklewe","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2217\/imt-2016-0020","article-title":"Immunotherapeutic implications of IL-6 blockade for cytokine storm","volume":"8","author":"Tanaka","year":"2016","journal-title":"Immunotherapy"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(03)15326-3","article-title":"Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock","volume":"363","author":"Pathan","year":"2004","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/17474086.2019.1585238","article-title":"Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy","volume":"12","author":"Acharya","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/ITT.S202015","article-title":"Cytokine Release Syndrome: Current Perspectives","volume":"8","author":"Murthy","year":"2019","journal-title":"Immunotargets Ther."},{"key":"ref_70","unstructured":"(2023, June 08). Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, Available online: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf."},{"key":"ref_71","unstructured":"(2023, June 08). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, Available online: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/ped.13064","article-title":"Hemophagocytic lymphohistiocytosis: Pathogenesis, diagnosis, and management","volume":"58","author":"Morimoto","year":"2016","journal-title":"Pediatr. Int."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/00043426-199302000-00012","article-title":"Hypercytokinemia in hemophagocytic syndrome","volume":"15","author":"Fujiwara","year":"1993","journal-title":"Am. J. Pediatr. Hematol. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/BOR.0b013e32834dd37e","article-title":"Not all hemophagocytes are created equally: Appreciating the heterogeneity of the hemophagocytic syndromes","volume":"24","author":"Canna","year":"2012","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1182\/blood.2022016421","article-title":"HLH treatment: Smarter, not harder","volume":"139","author":"Henderson","year":"2022","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: Consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1182\/blood.2021014860","article-title":"A study of ruxolitinib response\u2013based stratified treatment for pediatric hemophagocytic lymphohistiocytosis","volume":"139","author":"Zhang","year":"2022","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-17-3202","article-title":"Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody\u2013Drug Conjugates","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol. Ther."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/17\/5539\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:39:12Z","timestamp":1760128752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/17\/5539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":86,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["jcm12175539"],"URL":"https:\/\/doi.org\/10.3390\/jcm12175539","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,25]]}}}